David S Ettinger, M.D.

Selected Publications

View all on PubMed

Ettinger, D.S. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist. 2006 Apr;11(4):358-373.

Ettinger, D.S.; Aisner, J. Changing face of small-cell lung cancer: real and artifact. J Clin Oncol. 2006 Oct 1;24(28):4526-4527.

Ettinger, D.S.; Bepler, G.; Bueno, R.; Chang, A.; Chang, J.Y.; Chirieac, L.R.; D''Amico, T.A.; Demmy, T.L.; Feigenberg, S.J.; Grannis, F.W., Jr.; Jahan, T.; Jahanzeb, M.; Kessinger, A.; Komaki, R.; Kris, M.G.; Langer, C.J.; Le, Q.T.; Martins, R.; Otterson, G.A.; Robert, F.; Sugarbaker, D.J.; Wood, D.E. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul;4(6):548-582.

Johnson, B.E.; Crawford, J.; Downey, R.J.; Ettinger, D.S.; Fossella, F.; Grecula, J.C.; Jahan, T.; Kalemkerian, G.P.; Kessinger, A.; Koczywas, M.; Langer, C.J.; Martins, R.; Marymont, M.H.; Niell, H.B.; Ramnath, N.; Robert, F.; Williams, C.C., Jr. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul;4(6):602-622.

Kraybill, W.G.; Harris, J.; Spiro, I.J.; Ettinger, D.S.; DeLaney, T.F.; Blum, R.H.; Lucas, D.R.; Harmon, D.C.; Letson, G.D.; Eisenberg, B. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006 Feb 1;24(4):619-625.

Blakeley, J.; Laterra, J. Neurotoxicities. In: Ettinger, D.S.; Donehower, R., editors, Current Cancer in Therapeutics: Springer; 2007.
Brahmer, J.R.; Ettinger, D.S. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology. 2007 May;12(3):320-325.

Dunbar, E.; Laterra, J. Malignant glioma. In: Ettinger, D.S.; Donehower, R., editors: Current Cancer Therapeutics; 2007. p. In press.
Juergens, R.; Brahmer, J.; Ettinger, D. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol. 2007 Apr;59(5):621-629.

Brahmer, J.R. Lung Cancer. In: Donehower, R.; Ettinger, D., editors. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.

Brandes, J.C.; Yung, R.C. Pulmonary and Cardiovascular Complications of Cancer Therapy. In: Ettinger, D.; Donehower, R., editors, Current Cancer Therapeutics, Fifth Edition: Current Medicine, LLC; 2008.

Dhall, G.; Finlay, J.L.; Dunkel, I.J.; Ettinger, L.J.; Kellie, S.J.; Allen, J.C.; Egeler, R.M.; Arceci, R.J. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008 Jan;50(1):72-79.

el-Shami, K.; Forastiere, A.A. Head and Neck Cancer. In: Ettinger, D., et al, editor. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.

Ettinger, D.S.; Akerley, W.; Bepler, G.; Chang, A.; Cheney, R.T.; Chirieac, L.R.; D''Amico, T.A.; Demmy, T.L.; Feigenberg, S.J.; Figlin, R.A.; Govindan, R.; Grannis, F.W., Jr.; Jahan, T.; Jahanzeb, M.; Kessinger, A.; Komaki, R.; Kris, M.G.; Langer, C.J.; Le, Q.T.; Martins, R.; Otterson, G.A.; Patel, J.D.; Robert, F.; Sugarbaker, D.J.; Wood, D.E. Non-small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):228-269.

Ettinger, D.S.; Grunberg, S.M.; Hauber, A.B.; Mohamed, A.F. Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings. Support Care Cancer. 2008 Sep 2.
Le, D.; Kim, P.; Jaffee, E.M. Current Cancer Therapeutics. In: David Ettinger, R.D., editor, Cancer Vaccines. Philadelphia: Current Medicine, LLC; 2008.

Messersmith, W.A.; Jimeno, A.; Ettinger, D.; Laheru, D.; Brahmer, J.; Lansey, D.; Khan, Y.; Donehower, R.C.; Elsayed, Y.; Zannikos, P.; Hidalgo, M. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Dec;63(1):181-188.

Pili, R., J. Walczak, M. A. Carducci, and S. R. Denmeade. Genitourinary Cancer. In: Donhower, D.E.a.R., editor, Current Cancer in Therapeutics. Philadelphia: Current Medicine Group; 2008.

Choy, H.; Jain, A.K.; Moughan, J.; Curran, W.; Whipple, G.; Demas, W.F.; Ettinger, D.S. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol. 2009 Jan;4(1):80-86.

Guarino, M.J.; Schneider, C.J.; Hosford, M.D.; Brahmer, J.R.; Rudin, C.M.; Finkenstein, F.G.; Philip-Norton, R.E.; Lue, H.; Weber, M.R.; Ettinger, D.S. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14(2):119-124.

Sandford, G.R.; Schumacher, U.; Ettinger, J.; Brune, W.; Hayward, G.S.; Burns, W.H.; Voigt, S. Deletion of the rat cytomegalovirus immediate early 1 gene results in a virus capable of establishing latency but with lower levels of acute virus replication and latency that compromise reactivation efficiency. J Gen Virol. 2009 Nov 18.

Aisner, S.C.; Dahlberg, S.; Hameed, M.R.; Ettinger, D.S.; Schiller, J.H.; Johnson, D.H.; Aisner, J.; Loehrer, P.J. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol. 2010 Jun;5(6):885-892.

Balmanoukian, A.; Ettinger, D.S. Managing the patient with borderline resectable lung cancer. Oncology (Williston Park). 2010 Mar;24(3):234-241.

Ettinger, D.S. Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer. 2010 Jun;68(3):332-337.

Ettinger, D.S.; Akerley, W.; Bepler, G.; Blum, M.G.; Chang, A.; Cheney, R.T.; Chirieac, L.R.; D''Amico, T.A.; Demmy, T.L.; Ganti, A.K.; Govindan, R.; Grannis, F.W., Jr.; Jahan, T.; Jahanzeb, M.; Johnson, D.H.; Kessinger, A.; Komaki, R.; Kong, F.M.; Kris, M.G.; Krug, L.M.; Le, Q.T.; Lennes, I.T.; Martins, R.; O''Malley, J.; Osarogiagbon, R.U.; Otterson, G.A.; Patel, J.D.; Pisters, K.M.; Reckamp, K.; Riely, G.J.; Rohren, E.; Simon, G.R.; Swanson, S.J.; Wood, D.E.; Yang, S.C. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul;8(7):740-801.
Ettinger, D.S.; Akerley, W.; Bepler, G.; Blum, M.G.; Chang, A.; Cheney, R.T.; Chirieac, L.R.; D''Amico, T.A.; Demmy, T.L.; Govindan, R.; Grannis, F.W., Jr.; Jahan, T.; Johnson, D.H.; Kessinger, A.; Komaki, R.; Kong, F.M.; Kris, M.G.; Krug, L.M.; Le, Q.T.; Lennes, I.T.; Martins, R.; O''Malley, J.; Osarogiagbon, R.U.; Otterson, G.A.; Patel, J.D.; Pisters, K.M.; Reckamp, K.; Riely, G.J.; Rohren, E.; Swanson, S.J.; Wood, D.E.; Yang, S.C. Thymic malignancies. J Natl Compr Canc Netw. 2010 Nov;8(11):1302-1315.

Ettinger, D.S.; Jotte, R.; Lorigan, P.; Gupta, V.; Garbo, L.; Alemany, C.; Conkling, P.; Spigel, D.R.; Dudek, A.Z.; Shah, C.; Salgia, R.; McNally, R.; Renschler, M.F.; Oliver, J.W. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010 May 20;28(15):2598-2603.

Hann, C.L. Managing Risk-What if My Cancer Comes Back?: Jones and Bartlett; 2010.

Kraybill, W.G.; Harris, J.; Spiro, I.J.; Ettinger, D.S.; DeLaney, T.F.; Blum, R.H.; Lucas, D.R.; Harmon, D.C.; Letson, G.D.; Eisenberg, B. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010 Oct 1;116(19):4613-4621.